Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Blood

• Publication date

  2009-05-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2008-06-161505PMID 19270264PMCID PMC2686191
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

  2007cited by this paper
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

  2007cited by this paper
• Integrating cell-signalling pathways with NF-kappaB and IKK function.

  2007cited by this paper
• Nuclear factor-kappaB in development, prevention, and therapy of cancer.

  2007cited by this paper
• Integrating cell-signalling pathways with NF-κB and IKK function

  2007cited by this paper
• Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma

  2007cited by this paper
• Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

  2007cited by this paper
• The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis

  2007cited by this paper
• Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.

  2007cited by this paper
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007cited by this paper
• Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.

  2007cited by this paper
• Nuclear Factor-κB in Development, Prevention, and Therapy of Cancer

  2007cited by this paper
• MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.

  2006cited by this paper
• Targeting aurora kinases as therapy in multiple myeloma.

  2006cited by this paper
• IKKα Regulates the Mitotic Phase of the Cell Cycle by Modulating Aurora A Phosphorylation

  2006cited by this paper
• NF-kappaB and IKK as therapeutic targets in cancer.

  2006cited by this paper
• NF-κB and IKK as therapeutic targets in cancer

  2006cited by this paper
• Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

  2006cited by this paper
• Aberrant NF- κ B Signaling in Lymphoma: Mechanisms, Consequences and Therapeutic Implications

  2006cited by this paper
• MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo

  2006cited by this paper
• A Selective Small Molecule IκB Kinase β Inhibitor Blocks Nuclear Factor κB-Mediated Inflammatory Responses in Human Fibroblast-Like Synoviocytes, Chondrocytes, and Mast Cells

  2006cited by this paper
• A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.

  2006cited by this paper
• NF-κB: linking inflammation and immunity to cancer development and progression

  2005cited by this paper
• A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

  2005cited by this paper
• Wnts induce migration and invasion of myeloma plasma cells.

  2005cited by this paper
• NF-kappaB: linking inflammation and immunity to cancer development and progression.

  2005cited by this paper
• Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

  2005cited by this paper
• Antimyeloma activity of heat shock protein-90 inhibition.

  2005cited by this paper
• 1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo.

  2005cited by this paper
• TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.

  2004cited by this paper
• Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.

  2004cited by this paper
• Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment

  2004cited by this paper
• IκB kinases: key regulators of the NF-κB pathway

  2004cited by this paper
• Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.

  2004cited by this paper
• Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation.

  2004cited by this paper
• Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation

  2004cited by this paper
• IkappaB kinases: key regulators of the NF-kappaB pathway.

  2004cited by this paper
• IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf.

  2003cited by this paper
• NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

  2003cited by this paper
• Wnt signaling in B-cell neoplasia

  2003cited by this paper
• Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.

  2003cited by this paper
• The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

  2003cited by this paper
• Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

  2003cited by this paper
• NF-kappa B as a therapeutic target in multiple myeloma.

  2002cited by this paper
• NF-κB as a Therapeutic Target in Multiple Myeloma*

  2002cited by this paper
• Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

  2002cited by this paper
• NF-kappaB at the crossroads of life and death.

  2002cited by this paper
• NF-κB at the crossroads of life and death

  2002cited by this paper
• Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

  2002cited by this paper
• Molecular sequelae of proteasome inhibition in human multiple myeloma cells

  2002cited by this paper
• Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity*

  2001cited by this paper
• Regulation of β-Catenin Function by the IκB Kinases*

  2001cited by this paper
• NF-κB and cell-cycle regulation: the cyclin connection

  2001cited by this paper
• Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity.

  2001cited by this paper
• NF-kappaB and cell-cycle regulation: the cyclin connection.

  2001cited by this paper
• Regulation of beta-catenin function by the IkappaB kinases.

  2001cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)

  2000cited by this paper
• IκB Kinase α (IKKα) Regulation of IKKβ Kinase Activity

  2000cited by this paper
• IkB Kinase a (IKKa) Regulation of IKKb Kinase Activity

  2000cited by this paper
• Bcl-2 and Bcl-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-kappaB.

  1999cited by this paper
• NF-κB Function in Growth Control: Regulation of Cyclin D1 Expression and G0/G1-to-S-Phase Transition

  1999cited by this paper
• Bcl-2 and Bcl-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-κB

  1999cited by this paper
• The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation.

  1997cited by this paper
• The IκB Kinase Complex (IKK) Contains Two Kinase Subunits, IKKα and IKKβ, Necessary for IκB Phosphorylation and NF-κB Activation

  1997cited by this paper
• Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.

  1996cited by this paper
• The NF-kappa B and I kappa B proteins: new discoveries and insights.

  1996cited by this paper
• THE NF-κB AND IκB PROTEINS: New Discoveries and Insights

  1996cited by this paper

• Brazilin-Ce nanoparticles attenuate inflammation by de/anti-phosphorylation of IKKβ.

  2024cites this paper
• Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors

  2024cites this paper
• Review of Phytochemicals Present in Psidium guajava Plant and Its Mechanism of Action on Medicinal Activities

  2023cites this paper
• Melatonin synergistically enhances docetaxel induced endoplasmic reticulum stress to promote apoptosis by suppressing NF‐κB activation in cervical cancer

  2023cites this paper
• Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities.

  2021cites this paper
• Signaling Pathway Mediating Myeloma Cell Growth and Survival

  2021influential citation
• Posttranslational Modifications Associated With Cancer and Their Therapeutic Implications

  2019cites this paper
• The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

  2019cites this paper
• Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets

  2018cites this paper
• Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies

  2018cites this paper
• The NF-κB Activating Pathways in Multiple Myeloma

  2018cites this paper
• The power of proteasome inhibition in multiple myeloma

  2018cites this paper
• Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma

  2018cites this paper
• Running title: Classical/Alternative NFkB pathways in MM

  2017cites this paper
• Die Bedeutung des multi-site docking Proteins Gab1 in der Epo-, Jak2-V617F- und IL-6-induzierten Signaltransduktion

  2017cites this paper
• Beta-Catenin and the Survival of Hepatocytes

  2017cites this paper
• Developing novel agents targeting the NF-κB pathway for the treatment of multiple myeloma

  2017cites this paper
• HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

  2017cites this paper
• An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

  2017cites this paper
• Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma

  2017cites this paper
• The proteasome and proteasome inhibitors in multiple myeloma

  2017cites this paper
• Anti-cancer effects of Staphylococcal Enterotoxin type B on U266 cells co-cultured with Mesenchymal Stem Cells.

  2017cites this paper
• NIBP impacts on the expression of E-cadherin, CD44 and vimentin in colon cancer via the NF-κB pathway.

  2016cites this paper
• MULTIPLE MYELOMA ( P KAPOOR , SECTION EDITOR ) Signaling Pathways and Emerging Therapies in Multiple Myeloma

  2016cites this paper
• Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma

  2016cites this paper
• Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma

  2015cites this paper
• Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

  2015cites this paper
• Transcriptional repression by the HDAC4–RelB–p52 complex regulates multiple myeloma survival and growth

  2015cites this paper
• Genomic heterogeneity in multiple myeloma.

  2015cites this paper
• Unexpected functions of nuclear factor-&kgr;B during germinal center B-cell development: implications for lymphomagenesis

  2015cites this paper
• Characterization of the enhanced apoptotic response to azidothymidine by pharmacological inhibition of NF-kB.

  2015cites this paper
• Drug Resistance in Multiple Myeloma: How to Cross the

  2015cites this paper
• Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications.

  2015cites this paper
• IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma.

  2014cites this paper
• The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB

  2014cites this paper
• The Novel IKK 2 Inhibitor LY 2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NFk B

  2014cites this paper
• Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB

  2014cites this paper
• IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells

  2014cites this paper
• Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

  2014cites this paper
• JNK signalling in cancer: in need of new, smarter therapeutic targets

  2014cites this paper
• Human umbilical cord blood-derived stromal cells: A new resource for the proliferation and apoptosis of myeloma cells

  2014cites this paper
• therapeutic option in multiple myeloma is a promising α Blockade of XBP1 splicing by inhibition of IRE1

  2013cites this paper
• Role of NF-κB in Tumorigenesis

  2013cites this paper
• Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple Myeloma

  2013influential citation
• BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

  2013cites this paper
• Molecularly-targeted Strategy and NF-κB in lymphoid malignancies.

  2013cites this paper
• Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL.

  2013cites this paper
• Aurora and IKK kinases cooperatively interact to protect Multiple Myeloma cells from Apo 2 L / TRAIL Running title : Aurora blockade sensitizes Myeloma cells to TRAIL

  2013cites this paper
• The IκB kinase complex in NF‐κB regulation and beyond

  2013cites this paper
• The IKK Inhibitor Bay 11-7082 Induces Cell Death Independent from Inhibition of Activation of NFκB Transcription Factors

  2013cites this paper
• Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia

  2013cites this paper
• Biologic impact of proteasome inhibition in MM cells - from the aspects of preclinical studies

  2012cites this paper
• Cell Signaling & Molecular Targets in Cancer

  2012cites this paper
• Understanding the molecular biology of myeloma and its therapeutic implications

  2012cites this paper
• Cancer Therapy : Preclinical Dual Inhibition of Canonical and Noncanonical NFk B Pathways Demonstrates Signi fi cant Antitumor Activities in Multiple Myeloma

  2012cites this paper
• Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma

  2012cites this paper
• Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.

  2012cites this paper
• Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

  2012cites this paper
• The kinase NIK as a therapeutic target in multiple myeloma

  2011cites this paper
• Role of NF-κB in the skeleton

  2011cites this paper
• A Cytosolic ATM/NEMO/RIP1 Complex Recruits TAK1 To Mediate the NF-κB and p38 Mitogen-Activated Protein Kinase (MAPK)/MAPK-Activated Protein 2 Responses to DNA Damage

  2011cites this paper
• Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.

  2011cites this paper
• GLI2 Transcription Factor Mediates Cytokine Cross-talk in the Tumor Microenvironment*

  2011cites this paper
• The role of inflammation in the pathogenesis of lung cancer

  2011cites this paper
• Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy

  2011cites this paper
• Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

  2011cites this paper
• Novel therapies in MM: from the aspect of preclinical studies

  2011cites this paper
• Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics

  2011cites this paper
• Investigating the cancer stem cell hypothesis in canine tumours

  2011cites this paper
• NF-κB addiction and its role in cancer: ‘one size does not fit all’

  2011cites this paper
• The Role of Rip2 Protein in the Nod Mediated Innate Immune Response: A Dissertation

  2010cites this paper
• A proto-oncogene BCL 6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

  2010cites this paper
• Cross-Regulation Between Wnt and NF-κB Signaling Pathways.

  2010cites this paper
• Survival of Human Multiple Myeloma Cells Is Dependent on MUC1 C-Terminal Transmembrane Subunit Oncoprotein Function

  2010influential citation
• The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy

  2010cites this paper
• Classical and/or alternative NF- (cid:1) B pathway activation in multiple myeloma

  2010cites this paper
• A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.

  2010cites this paper
• A critical role for the NFkB pathway in multiple myeloma

  2010cites this paper
• The role of the bone marrow microenvironment in the establishment and progression of multiple myeloma

  2010cites this paper
• Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

  2010cites this paper
• A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

  2009cites this paper
• The NF-kappaB-independent functions of IKK subunits in immunity and cancer.

  2009cites this paper
• Classical and/or Alternative NFkB pathway activation in multiple myeloma

  2009cites this paper
• Title: the Novel Ikk2 Inhibitor Ly2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of Nf-kb Authors and Affiliations

  year unknowncites this paper